Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMCR
Strong SellSinkerImmunocore Holdings plc · Healthcare · United Kingdom · $1.9B · Avg Vol: $13M/d
COMPANY DESCRIPTION
Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing novel T-cell receptor (TCR) based immunotherapies for cancer and infectious diseases, with its lead product, Kimmtrak, approved for uveal melanoma. The company possesses a proprietary ImmTAX platform, which allows it to engineer high-affinity TCRs to target intracellular antigens, a significant competitive advantage over traditional antibody therapies. As a leading innovator in TCR-based immunotherapies, Immunocore is a clinical and commercial-stage biotech with a validated platform, holding significant intellectual property in a cutting-edge field.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 174.4M | 249.4M | 310.2M | 400.0M | 31.9% | 430.8M | 451.7M | 489.2M | 10.6% |
| EPS | -1.09 | -1.13 | -1.02 | -0.71 | — | -0.36 | — | — | — |
| Shares | 48.1M | 49.7M | 50.1M | 50.7M | +5.4% | 51.5M | — | — | — |
| Debt | 81.4M | 85.0M | 432.7M | 436.7M | 75.0% | 435.0M | — | — | — |
| Equity | 338.9M | 368.8M | 360.7M | 381.0M | 4.0% | — | — | — | — |
| Op CF | -49.2M | 2.9M | 26.1M | -10.7M | 786.4% | -35.0M | — | — | — |
| Inv CF | -2.2M | -5.4M | -355.1M | -16.3M | — | — | — | — | — |
| Fin CF | 145.4M | 34.3M | 343.9M | 12.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMCR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMCR | Immunocore Holdings plc(you) | $1.9B | 17 | Strong Sell |
| OXB.L | Oxford Biomedica plc | $859M | 14 | Strong Sell |
| ONT.L | Oxford Nanopore Technologies plc | $2.3B | 32 | Sell |
| SLN | Silence Therapeutics plc | $834M | 24 | Sell |
| AUTL | Autolus Therapeutics plc | $623M | 30 | Sell |
| AVCT.L | Avacta Group Plc | $433M | 10 | Strong Sell |
| BCYC | Bicycle Therapeutics plc | $294M | 10 | Strong Sell |
| GNS.L | Genus plc | $2.1B | 61 | Hold |
| ROIV | Roivant Sciences Ltd. | $25.1B | 21 | Sell |
| 4BB.L | 4basebio PLC | $110M | 10 | Strong Sell |
Peer medians: ROE -1.8% · P/E 24.4x · Gross margin 56.8%